FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1737745909> ?p ?o ?g. }

• W1737745909 endingPage "517" @default.
• W1737745909 startingPage "507" @default.
• W1737745909 abstract "( Headache 2011;51:507‐517) Objective.— To evaluate the efficacy and tolerability of MAP0004 compared with placebo for a single migraine in adult migraineurs: The FREEDOM‐301 Study. Background.— Acute treatment of migraine remains a clinical challenge despite the availability of triptans and other agents. Injectable dihydroergotamine, although effective, is considered invasive and inconvenient, and intranasal dihydroergotamine is associated with inconsistent systemic dosage delivery. MAP0004 is an orally inhaled formulation of dihydroergotamine delivered to the systemic circulation. In a phase 2 study, MAP0004 provided significant early onset of pain relief (10 minutes, P < .05) and sustained pain relief for up to 48 hours with a favorable adverse event profile. Methods.— A phase 3, randomized, double‐blind, placebo‐controlled, parallel‐group, single‐attack, outpatient study of MAP0004, an inhaled dihydroergotamine was conducted at 102 sites in 903 adults with a history of episodic migraine. Patients were randomized (1:1) to receive MAP0004 (0.63 mg emitted dose; 1.0 mg nominal dose) or placebo, administered after onset of a migraine headache with moderate to severe pain. The co‐primary endpoints were patient‐assessed pain relief and absence of photophobia, phonophobia, and nausea at 2 hours after treatment. Results.— A total of 903 patients (450 active, 453 placebo) were randomized, and 792 (395 active, 397 placebo) experienced a qualifying migraine. MAP0004 was superior to placebo in all 4 co‐primary endpoints: pain relief (58.7% vs 34.5%, P < .0001), phonophobia free (52.9% vs 33.8%, P < .0001), photophobia free (46.6% vs 27.2%, P < .0001), and nausea free (67.1% vs 58.7%, P = .0210). Additionally, significantly more patients were pain‐free at 2 hours following treatment with MAP0004 than with placebo (28.4% vs 10.1%, P < .0001). MAP0004 was well tolerated; no drug‐related serious adverse events occurred. Conclusions.— In this study, MAP0004 was effective and well tolerated for the acute treatment of migraine with or without aura, providing statistically significant pain relief and freedom from photophobia, phonophobia, and nausea in adults with migraine compared with placebo." @default.
• W1737745909 created "2016-06-24" @default.
• W1737745909 creator A5015102287 @default.
• W1737745909 creator A5023730853 @default.
• W1737745909 creator A5057290642 @default.
• W1737745909 creator A5059017023 @default.
• W1737745909 creator A5063765693 @default.
• W1737745909 creator A5064341657 @default.
• W1737745909 creator A5064830047 @default.
• W1737745909 date "2011-04-01" @default.
• W1737745909 modified "2023-10-17" @default.
• W1737745909 title "MAP0004, Orally Inhaled DHE: A Randomized, Controlled Study in the Acute Treatment of Migraine" @default.
• W1737745909 cites W1981638246 @default.
• W1737745909 cites W1999794366 @default.
• W1737745909 cites W2003262566 @default.
• W1737745909 cites W2025168050 @default.
• W1737745909 cites W2041898141 @default.
• W1737745909 cites W2047455969 @default.
• W1737745909 cites W204766049 @default.
• W1737745909 cites W2052258972 @default.
• W1737745909 cites W2062955354 @default.
• W1737745909 cites W2064236558 @default.
• W1737745909 cites W2067674696 @default.
• W1737745909 cites W2070285328 @default.
• W1737745909 cites W2082901679 @default.
• W1737745909 cites W2084476204 @default.
• W1737745909 cites W2086126627 @default.
• W1737745909 cites W2087030391 @default.
• W1737745909 cites W2102298775 @default.
• W1737745909 cites W2116452736 @default.
• W1737745909 cites W2135858080 @default.
• W1737745909 cites W2141991917 @default.
• W1737745909 cites W2158846562 @default.
• W1737745909 cites W2162104155 @default.
• W1737745909 cites W2166530830 @default.
• W1737745909 doi "https://doi.org/10.1111/j.1526-4610.2011.01869.x" @default.
• W1737745909 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21457235" @default.
• W1737745909 hasPublicationYear "2011" @default.
• W1737745909 type Work @default.
• W1737745909 sameAs 1737745909 @default.
• W1737745909 citedByCount "87" @default.
• W1737745909 countsByYear W17377459092012 @default.
• W1737745909 countsByYear W17377459092013 @default.
• W1737745909 countsByYear W17377459092014 @default.
• W1737745909 countsByYear W17377459092015 @default.
• W1737745909 countsByYear W17377459092016 @default.
• W1737745909 countsByYear W17377459092017 @default.
• W1737745909 countsByYear W17377459092018 @default.
• W1737745909 countsByYear W17377459092019 @default.
• W1737745909 countsByYear W17377459092020 @default.
• W1737745909 countsByYear W17377459092021 @default.
• W1737745909 countsByYear W17377459092022 @default.
• W1737745909 countsByYear W17377459092023 @default.
• W1737745909 crossrefType "journal-article" @default.
• W1737745909 hasAuthorship W1737745909A5015102287 @default.
• W1737745909 hasAuthorship W1737745909A5023730853 @default.
• W1737745909 hasAuthorship W1737745909A5057290642 @default.
• W1737745909 hasAuthorship W1737745909A5059017023 @default.
• W1737745909 hasAuthorship W1737745909A5063765693 @default.
• W1737745909 hasAuthorship W1737745909A5064341657 @default.
• W1737745909 hasAuthorship W1737745909A5064830047 @default.
• W1737745909 hasConcept C126322002 @default.
• W1737745909 hasConcept C141071460 @default.
• W1737745909 hasConcept C142724271 @default.
• W1737745909 hasConcept C168563851 @default.
• W1737745909 hasConcept C197934379 @default.
• W1737745909 hasConcept C202061045 @default.
• W1737745909 hasConcept C204787440 @default.
• W1737745909 hasConcept C27081682 @default.
• W1737745909 hasConcept C2777119127 @default.
• W1737745909 hasConcept C2777350023 @default.
• W1737745909 hasConcept C2778375690 @default.
• W1737745909 hasConcept C2778541695 @default.
• W1737745909 hasConcept C2779631551 @default.
• W1737745909 hasConcept C2780564907 @default.
• W1737745909 hasConcept C2780580376 @default.
• W1737745909 hasConcept C2780590625 @default.
• W1737745909 hasConcept C2781302852 @default.
• W1737745909 hasConcept C2991744798 @default.
• W1737745909 hasConcept C42219234 @default.
• W1737745909 hasConcept C71924100 @default.
• W1737745909 hasConceptScore W1737745909C126322002 @default.
• W1737745909 hasConceptScore W1737745909C141071460 @default.
• W1737745909 hasConceptScore W1737745909C142724271 @default.
• W1737745909 hasConceptScore W1737745909C168563851 @default.
• W1737745909 hasConceptScore W1737745909C197934379 @default.
• W1737745909 hasConceptScore W1737745909C202061045 @default.
• W1737745909 hasConceptScore W1737745909C204787440 @default.
• W1737745909 hasConceptScore W1737745909C27081682 @default.
• W1737745909 hasConceptScore W1737745909C2777119127 @default.
• W1737745909 hasConceptScore W1737745909C2777350023 @default.
• W1737745909 hasConceptScore W1737745909C2778375690 @default.
• W1737745909 hasConceptScore W1737745909C2778541695 @default.
• W1737745909 hasConceptScore W1737745909C2779631551 @default.
• W1737745909 hasConceptScore W1737745909C2780564907 @default.
• W1737745909 hasConceptScore W1737745909C2780580376 @default.
• W1737745909 hasConceptScore W1737745909C2780590625 @default.
• W1737745909 hasConceptScore W1737745909C2781302852 @default.

• next